T6A Biomarker for Detection of Bacterial Infection in Newborn Infants

NCT07670624 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2026-08-17

No results posted yet for this study

Summary

This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.

Conditions

  • Sepsis
  • Newborn Sepsis
  • Biomarker Discovery

Sponsors & Collaborators

  • Wroclaw Medical University

    collaborator OTHER
  • Ludwig Boltzmann Gesellschaft

    collaborator OTHER
  • Salzburger Landeskliniken

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07670624 on ClinicalTrials.gov